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Recurrent Ventricular
Tachycardia After Catheter
Ablation in Post-Infarct
Cardiomyopathy
“Failure” of Ablation or
Progression of the Substrate?*
Edward P. Gerstenfeld, MD
San Francisco, California
The use of implantable cardioverter-defibrillators (ICD) in
patients with reduced ejection fraction after myocardial
infarction (MI) has been shown to reduce cardiovascular
death and total mortality (1). However, defibrillator shocks
for recurrent ventricular tachycardia (VT) can be painful and
anxiety provoking for patients. Antiarrhythmic therapy can
be used to prevent recurrent episodes of VT. However, such
therapy may be incomplete and is often associated with
adverse effects. Catheter ablation has the potential to
prevent recurrent VT without the need for long-term
antiarrhythmic therapy. According to the American Heart
Association consensus statement, catheter ablation is rec-
ommended “for symptomatic sustained monomorphic VT,
including VT terminated by an ICD, that recurs despite
antiarrhythmic drug therapy or when antiarrhythmic drugs
are not tolerated or not desired” (2).
See page 66
The mechanism of VT after MI in the vast majority of
patients is re-entry, which is facilitated by slow conduction
and block within a heterogeneous scar. Progressive fibrosis
and remodeling may lead to the development of VT many
years after the index event. Catheter ablation of VT seeks to
interrupt the critical channel or “isthmus” of slow conduc-
tion within a scar that supports the development and
maintenance of VT. Significant advances in VT mapping
and ablation have occurred over the past decade. In addition
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the critical isthmus during tolerated VT, the advent of
three-dimensional mapping systems has allowed ablation of
poorly tolerated or “unstable” VTs. Voltage maps can
delineate the scar boundaries, allowing the targeting of the
VT isthmus and exit sites during sinus rhythm (3). Newer
techniques may also target “channels” of relatively higher
voltage within scars (4) or signals containing “late poten-
tials” indicative of viable myocardium in a zone of slow
conduction. Percutaneous ventricular assist devices are also
being used to facilitate mapping during poorly tolerated VT
or in patients who have significant left ventricular dysfunc-
tion (5).
Despite these advances, however, the long-term success
rate of catheter ablation, when measured in terms of
freedom from any recurrent VT, remains suboptimal. The
VTACH (Ventricular Tachycardia Ablation in Addition to
Implantable Defibrillators in Coronary Heart Disease)
study reported by Kuck et al. (6) randomized patients with
VT after MI to receive ICD implantation alone versus
catheter ablation followed by ICD implantation. Although
recurrent VT was clearly reduced in the ablation arm, the
VT recurrence rate at 2 years was still 53%. Jaïs et al. (7)
ecently reported a new technique of catheter ablation,
rimarily targeting late fractionated potentials during sinus
hythm. Although complete elimination of these late po-
entials portended a better prognosis, the rate of recurrent
T or death at 2 years in the successful group was 45%.
Little is known about the reason for recurrent VT after
cutely “successful” catheter ablation. We know the success
ate is better for mappable VTs compared with unmappable
Ts (8) and that the success rate is best when all induced
Ts are targeted for ablation. However, there are several
easons VT may recur after ablation. The remodeling
rocess after MI is a complex one, and continued infarct
emodeling may lead to the formation of new VT circuits
hat were not present during the initial ablation session. It is
lso possible, given the poor reproducibility of programmed
timulation, that VTs which are not induced during the
nitial ablation session are clinically relevant and become
anifest much later. Although we know the majority of
e-entry circuits after MI are subendocardial, ablation le-
ions may be limited by the presence of subendocardial
brosis or thrombus, and incomplete lesions may lead to
ecurrences of the same clinical VT after ablation. Some VT
ircuits may be midmyocardial or epicardial, limiting endo-
ardial access to the critical isthmus. Finally, it is possible
hat ablation lesions are proarrhythmic, and that the cre-
tion of islands of unexcitable myocardium may create a
arrier for the development of new VTs after ablation.
Determining the reasons for recurrent VT after ablation
s challenging because it requires tracking electrocardio-
ram, mapping, and ablation data over many years. In this
ssue of the Journal, Yokokawa et al. (9) try to understand
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with prior MI.
The authors studied 98 patients referred for catheter
ablation of VT between 2004 and 2011 (9). All patients had
a history of anterior (33%) or inferior (66%) MI and VT
that recurred despite antiarrhythmic therapy. In these pa-
tients, they were able to induce 725 VTs, 105 “clinical” and
the remaining “nonclinical” as determined predominantly
from intracardiac electrogram morphology and cycle-length
analysis. Critical endocardial sites were identified in 71% of
the clinical VTs and only 45% of the nonclinical VTs. These
critical sites were identified by entrainment mapping in 15%
of the clinical VTs and 4% of the nonclinical VTs; the
remainder were identified with pace-mapping. Ablation was
directed focally to the VT isthmus during tolerated VT or
clustered around areas of good pace-maps (10 of 12 match)
for poorly tolerated VTs. After ablation, there was no
inducible VT with up to 4 extrastimuli at 2 right ventricular
sites in 63% of patients. Impressively, none of the clinical
VTs were inducible after ablation. After ablation, VT
recurred in 33 patients (34%): a new VT in 16 (48%), the
clinical VT only in 7 (21%), and both clinical and nonclini-
cal VTs in 10 (30%). Fourteen of the patients with recurrent
VT underwent repeat ablation. Interestingly, new VTs that
were not documented in the prior study were inducible in all
patients. The critical isthmus for the recurrent VT was
“adjacent” to prior ablation lesions in the majority (53%) of
patients, at sites of a prior VT isthmus in 15%, and new sites
remote from the original VT in the remaining 32%. After
repeat ablation, the final success rate with catheter ablation
was 77%.
There are certainly several limitations to the study (9): use
f intracardiac electrogram morphology is far from perfect
or distinguishing clinical from nonclinical VTs. The vast
ajority of VTs were targeted based on pace-map criteria,
nd these criteria (match of 10 of 12 leads) were not very
pecific. Therefore, many of the so-called critical sites may
ot have really represented the true VT isthmus. It is also
nclear why no critical site could be found for nearly 45% of
he induced VTs. The authors used an ablation approach of
lacing “clusters” of lesions at these critical sites, rather than
he more commonly described “linear” ablation through
ites of good pace-maps. In addition, there is some discon-
ect between the described strategy and the ablation lesions
hown in the maps depicted in Figures 2 and 3 of Yokakawa
t al. (9). The lesions placed in this large infarct seem to be
ore extensive than those described by the authors’ ap-
roach targeting areas of late potentials and pace-map
atches, making a clear understanding of their approach to
blation difficult. The alignment of 2 left ventricular elec-
roanatomic maps recorded years apart, accounting for
hanges in sampling density and left ventricular volume,
hich can account for 6-mm differences in the location of
critical” isthmus sites, is certainly prone to error.
Nevertheless, maintaining the intracardiac electrogramsor all the clinical and induced VTs, maintaining a uniformstimulation protocol, and maintaining detailed enough
maps over 7 years such that a comparison of VT isthmus
location was possible for patients undergoing repeat ablation
represents a truly Herculean effort. The authors should be
congratulated for providing new information about VT
recurrence after ablation.
So what have we learned from this ambitious study (9)?
The major learning points are the following: 1) the most
common origin of recurrent VT after catheter ablation is
adjacent to prior ablation lesions; and 2) the second most
common site of origin is from a new region not identified
during the original ablation session. The question is, how
can we use this information to improve outcome after VT
ablation? The origin of recurrent VTs “adjacent” to prior
ablative lesions raises 2 possibilities. Either ablation altered
the exit of the original VT circuit or ablation lesions created
proarrhythmic boundaries that supported the development
of new VTs in an already remodeled substrate. The authors
describe an ablation approach that applies “clusters” of
lesions at sites of good pace-maps. It is possible that a linear
pattern of lesions through sites of good pace-maps might be
less proarrhythmic. Achieving transmural lesions with com-
plete block in the left ventricle is challenging; however, an
endpoint of block across a linear lesion set may improve
ablation outcome by preventing the development of future
VTs. Use of intracardiac echocardiography and/or contact
force catheters could also improve the efficacy of ablation
lesions by ensuring adequate catheter stability during ablation.
Preventing the development of newly identified VTs at
distant sites is more challenging. This may occur either
because the recurrent VT was not induced during the initial
procedure or because evolving changes to the left ventricular
substrate over time led to the development of new VT
circuits. Some have advocated ablating all late potentials in
sinus rhythm as a strategy for VT ablation (7); this might
result in the prevention of future VTs by ablating regions of
slow conduction that might later support VT. Conversely,
such lesions may also have proarrhythmic potential. A more
extensive approach would involve ablation to “homogenize”
the entire scar, because the scar does not contribute to left
ventricular function, and any heterogeneous region might
serve to support a future VT. Use of cardiac magnetic
resonance imaging (10) or direct visualization to guide
ablation of heterogeneous zones capable of supporting VT
has also been described.
We have witnessed several innovations specific to pulmo-
nary vein isolation for treating atrial fibrillation over the past
few years, including development of the cryoballoon, laser
balloon, and the phased radiofrequency energy multielec-
trode catheters. New technology specific to VT ablation has
been lacking. Technologies that allow more detailed map-
ping of unstable VT, contiguous linear ablation with con-
firmation of adequate lesion formation, and better end-
points beyond programmed stimulation are needed. There
are also few randomized trials comparing the many available
VT ablation strategies. The 77% freedom from VT after
176 Gerstenfeld JACC Vol. 61, No. 1, 2013
Recurrent Ventricular Tachycardia After Ablation January 8, 2013:74–6ablation achieved by Yokakawa et al. (9) is indeed laudable,
but the authors have also reminded us that our current
understanding of VT in the setting of structural heart
disease remains incomplete. This is an area that should
become a priority for investigation in the next decade.
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